News & Updates

The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.

Use of metformin in nondiabetic breast cancer patients improves their clinical and pathological response to neoadjuvant AC-T chemotherapy, reveals a recent study.